¿Cuáles son los resultados de los ensayos de remdesivir para el tratamiento de la covid-19?
(What are the results of remdesivir trials for the treatment of covid-19?)
Primeras 5 respuestas:
-
This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.
-
elevated hepatic enzymes were the most frequent adverse drug reaction reported.
-
The first published clinical trial of remdesivir in severe COVID-19 did not show a mortality benefit [8] .
-
Preliminary clinical trial results suggest that there may be a favourable benefit-risk profile for remdesivir compared with placebo;
-
the results from the first randomized placebo-controlled trial from China were inconclusive [7] .
This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.
... CLINICAL QUESTION: What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020. CURRENT PRACTICE: Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. After ...
Ref: Remdesivir for severe covid-19: a clinical practice guideline [BMJ, 2020]elevated hepatic enzymes were the most frequent adverse drug reaction reported.
... In cohort studies of patients hospitalized for severe COVID-19 who were treated with compassionate-use remdesivir, elevated hepatic enzymes were the most frequent adverse drug reaction reported. 4,5 In the first randomized, double-blind, placebo-controlled clinical trial assessing the effect of intravenous remdesivir ...
Ref: cord_uid gr6aukp1 Hepatic Disorders With the Use of Remdesivir f... gr6aukp1 Hepatic Disorders With the Use of Remdesivir f... Name: title, dtype: object [BMJ, cord_uid gr6aukp1 2020 gr6aukp1 2020 Name: publish_time, dtype: object]The first published clinical trial of remdesivir in severe COVID-19 did not show a mortality benefit [8] .
... . This makes remdesivir effective against a range of coronaviruses [5] including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) [6] , and COVID-19 [7] . The first published clinical trial of remdesivir in severe COVID-19 did not show a mortality benefit [8] . ...
Ref: Remdesivir, a remedy or a ripple in severe COVID-19? [Expert opinion on investigational drugs, 2020-09-20]Preliminary clinical trial results suggest that there may be a favourable benefit-risk profile for remdesivir compared with placebo;
Preliminary clinical trial results suggest that there may be a favourable benefit-risk profile for remdesivir compared with placebo; however, data is limited at the current time.
Ref: Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment [Drug Saf, 2020-05-28]the results from the first randomized placebo-controlled trial from China were inconclusive [7] .
... Despite high expectations for remdesivir in treating COVID-19 [5, 6] , the results from the first randomized placebo-controlled trial from China were inconclusive [7] . However, results of a larger scale multicenter trial conducted by the National Institute of Allergy and Infectious Diseases, showed ...
Ref: Remdesivir Use Compared to Supportive Care in Hospitalized Patients with Severe COVID-19: A Single-Center Experience [Open Forum Infect Dis, 2020-08-06]In another trial, a shorter time to recovery in patients treated with remdesivir was observed (11 vs 15 days),
... significant (21 vs 23 days, HR 1.23, 95% CI 0.87-1.75), although the study was underpowered. In another trial, a shorter time to recovery in patients treated with remdesivir was observed (11 vs 15 days), with non-significant reduced mortality risk (8% vs 12%). Risk data were only available from one ...
Ref: Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment [Drug Saf, 2020]A study comprising 69 patientsfound that arbidol could improve the rate of discharge and without deaths occurred [9] .
... retrospective studies have discussed the antiviral effects and safety of arbidol in patients with COVID-19. A study comprising 69 patientsfound that arbidol could improve the rate of discharge and without deaths occurred [9] . Another study showed that the participant group that was given arbidol had a shorter duration ...
Ref: Treatments in the COVID-19 pandemic: an update on clinical trials [Expert opinion on emerging drugs, 2020-06-17]adverse events occurred in 66% and 64% of patients receiving remdesivir and placebo, respectively [19] .
... phase I studies. In a randomized, placebo-controlled trial of patients with severe COVID-19 in China, adverse events occurred in 66% and 64% of patients receiving remdesivir and placebo, respectively [19] . The most common adverse events were constipation (14% vs. 15%), AST elevation (5% vs. 12%), ...
Ref: That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19 [Infect Dis Ther, 2020-07-10]results from the phase III randomised clinical trial for this indication have been published [8] .
... and risks in order of considered originally developed for treatment of Ebola virus disease and results from the phase III randomised clinical trial for this indication have been published [8] . It has been shown to have broad spectrum in-vitro activity against several coronaviruses, including SARS-CoV-2 ...
Ref: Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment [Drug Saf, 2020-05-28]The primary outcome suggested a reduction in the median time to clinical improvement,
... placebo-controlled clinical trial studying remdesivir in the context of COVID-19 have been published [25] . The primary outcome suggested a reduction in the median time to clinical improvement, although this difference was non-significant (21 vs 23 days, HR=1.23, 95% CI: 0.87, 1.75). However, ...
Ref: Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment [Drug Saf, 2020-05-12]The outcomes were mortality, recovery rate, length of hospital stay and clinical outcome.
... (RCTs), prospective case series studies and case reports that evaluated use of remdesivir in COVID-19. The outcomes were mortality, recovery rate, length of hospital stay and clinical outcome. Though the drug remdesivir (RDV) is not approved by the FDA, still the "Emergency Use ...
Ref: Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences. [Mymensingh medical journal : MMJ, 2020-04-01]clinical improvement was observed in 36 of 53 patients (68%).
... In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead ...
Ref: Compassionate Use of Remdesivir for Patients with Severe Covid-19 [N Engl J Med, 2020]Currently, remdesivir is being investigated in ten randomized controlled trials against COVID-19.
... safety profile has been tested in Ebola patients and in compassionate use in COVID-19 patients. Currently, remdesivir is being investigated in ten randomized controlled trials against COVID-19. The dose regimen of remdesivir is an IV loading dose of 200 mg on day ...
Ref: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit [AAPS J, 2020]Remdesivir's pricing is based on a presumed reduction of hospital length of stay (LOS) by four days.
... Remdesivir has been granted emergency use authorization for treatment of severe COVID-19. Remdesivir"s pricing is based on a presumed reduction of hospital length of stay (LOS) by four days. But the Adaptive COVID-19 Treatment Trial (ACTT-1) that suggested this treatment benefit excluded patients who were expected to ...
Ref: Hospital length of stay for severe COVID-19: implications for Remdesivir's value [medRxiv : the preprint server for health sciences, 2020-08-12]In one multicenter, multinational series, 53 patients with severe COVID-19 received remdesivir for up to 10 days:
... In one multicenter, multinational series, 53 patients with severe COVID-19 received remdesivir for up to 10 days: 36 patients (68%) showed a clinical improvement (decreased requirement for oxygen support or hospital discharge) and of the 30 patients who were mechanically ventilated at baseline 17 (57%) were extubated ...
Ref: A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review [Life (Basel), 2020-08-09]results from the phase 3 randomised clinical trial for this indication have been published [8] .
... Remdesivir was originally developed for treatment of Ebola Virus Disease and results from the phase 3 randomised clinical trial for this indication have been published [8] . It has been shown to have broad spectrum in-vitro activity against several coronaviruses, including SARS-CoV-2 [6, 9, 10] in-vivo ...
Ref: Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment [Life (Basel), 2020-05-12]A total of seven ongoing and recruiting clinical trials of remdesivir (100-200 milligrams, intravenous [IV]) were included.
... 98.5% (κ = 0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven ongoing and recruiting clinical trials of remdesivir (100-200 milligrams, intravenous [IV]) were included. We identified the following primary outcomes: patients discharged (n = 2); time to clinical status ...
Ref: Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature [West J Emerg Med, 2020-05-20]The available observational and prospective data are conflicting,
... Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally ...
Ref: That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19 [Infect Dis Ther, 2020]Results did not show any significant difference between the 5-day and 10-day durations of remdesivir administration.
... (ClinicalTrials.gov number: NCT04292899), patients with severe COVID-19 who did not require mechanical ventilation were included. Results did not show any significant difference between the 5-day and 10-day durations of remdesivir administration. Due to the lack of a placebo control arm, the magnitude of remdesivir efficacy cannot ...
Ref: A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19 [Drug Des Devel Ther, 2020-08-06]the clinical improvement rate was 88% at day 28 [46] .
... patients (aged 0-17 years) with severe COVID-19 treated with compassionate use remdesivir (n = 77), the clinical improvement rate was 88% at day 28 [46] . Clinical recovery occurred in 80% of patients on ventilators/ECMO at baseline and in 87% of ...
Ref: Remdesivir: First Approval [Drugs, 2020-09-01]their results were conflicting.
... trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting. Thus, we conducted a network meta-analysis comparing the rate of clinical improvement among patients with ...
Ref: Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials [Virus Res, 2020]There are few phase 3 randomized double-blind placebo controlled trials on the way to investigate the safety and efficacy of remdesivir.
... no published studies that substantiate its activity in vivo until the time of this review. There are few phase 3 randomized double-blind placebo controlled trials on the way to investigate the safety and efficacy of remdesivir. Of which, one completed double blind, placebo controlled trial showed that remdesivir showed faster time ...
Ref: Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19? [Front. Pharmacol., 2020]64% of the patients needed invasive mechanical ventilation and the sample was correctly labeled as severe.
... et al. stated that Remdesivir may be useful in treating severe COVID-19 patients (15) . 64% of the patients needed invasive mechanical ventilation and the sample was correctly labeled as severe. This study showed that clinical improvement in milder cases were higher than that of more ...
Ref: Remdesivir Efficacy in Coronavirus Disease 2019 (COVID-19): A Systematic Review [Front. Pharmacol., 2020-06-16]Phase II and Phase III has been reached by 12 each clinical study (6) .
... in the Clinical Trial registry (ClinicalTrial. gov) out of which 20 are of interventional type. Phase II and Phase III has been reached by 12 each clinical study (6) . Recently, Gilead announced the result of Phase III clinical trial on Remdesivir that demonstrated similar ...
Ref: Status of Remdesivir: Not Yet Beyond Question! [Arch Med Res, 2020-09-21]Remdesivir has shown the most promising results
... no repurposed drug has been found that could significantly impact the course of this pandemic. Remdesivir has shown the most promising results and might now be an important tool with which to try to reduce the mortality ...
Ref: Clinical Trials of Repurposed Antivirals for SARS-CoV-2 [Antimicrob Agents Chemother, 2020-08-20]A total of 617 COVID-19 clinical trials were registered during the period from January 23 to April 24, 2020
... A total of 617 COVID-19 clinical trials were registered during the period from January 23 to April 24, 2020 and retrieved from the ChiCTR database. The number of these trial registrations increased rapidly during the first three months, and then increased gradually from March to April, especially reaching to ...
Ref: Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry [Emerging microbes & infections, 2020-07-22]Yeming Wang and colleagues 1 were unable to attain their primary endpoint of time to clinical improvement.
... In the first published placebo-controlled trial of remdesivir for treating severe COVID-19, Yeming Wang and colleagues 1 were unable to attain their primary endpoint of time to clinical improvement. Although admittedly underpowered due to early trial termination, remdesivir did not appear to affect rates of severe acute ...
Ref: Remdesivir and COVID-19 [Lancet, 2020-10-01]More than 600 clinical trials for potential therapeutics are underway and the results are expected soon.
... As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, ...
Ref: COVID-19 associated complications and potential therapeutic targets [Eur J Pharmacol, 2020]In a preliminary cohort study published by Grein et al., data of ethnicity was omitted for 53 patients (11) .
... interpreting the incidence, and clinical outcomes of minority groups in remdesivir COVID-19 trials (25) . In a preliminary cohort study published by Grein et al., data of ethnicity was omitted for 53 patients (11) . While the vetting for preliminary results was obtained from limited datasets the proportion of Black, ...
Ref: Randomized placebo-controlled trials of remdesivir in severe COVID-19 patients: A Systematic Review and Meta-analysis [Eur J Pharmacol, 2020-08-24]In different clinical trials, efficacy of remdesivir (GS-5734) against Ebola virus has been demonstrated.
... using available conventional therapeutics along with other treatment options may be useful to fight COVID-19. In different clinical trials, efficacy of remdesivir (GS-5734) against Ebola virus has been demonstrated. Moreover, remdesivir may be an effective therapy in vitro and in animal models infected by ...
Ref: A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19 [Drug Des Devel Ther, 2020]With an enrollment of 1063, this was the largest clinical trial to date for remdesivir [33] .
... a double-blind, randomized, placebo controlled trial where they used intravenous remdesivir hospitalized patients with COVID-19. With an enrollment of 1063, this was the largest clinical trial to date for remdesivir [33] . This study showed a 31% faster recovery (11 days for patients treated with remdesivir compared ...
Ref: Treatment Options for COVID-19 in Patients with Reduced or Absent Kidney Function [Adv Chronic Kidney Dis, 2020-09-17]Administering 1 day after the onset of the disease, lung virus titers decreased significantly,
... the Ces1c (−/−) mouse SARS model, the preventive treatment trial of remdesivir achieved satisfactory results. Administering 1 day after the onset of the disease, lung virus titers decreased significantly, Fig. 2 . SARS-CoV-2 invasion process and how remdesivir works 1 SARS-CoV-2 enters target cells ...
Ref: Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence [Travel Med Infect Dis, 2020-04-02]Remdesivir was administrated for 5 or 10 days in patients with severe Covid-19.
... of the phase 3 trial (randomised, open-label) on the use of remdesivir in hospitalised patients. Remdesivir was administrated for 5 or 10 days in patients with severe Covid-19. Patients who received concomitant treatment (within 24 h before starting remdesivir treatment) with other potentially ...
Ref: Treatment for COVID-19: An overview [Eur J Pharmacol, 2020-12-15]We will include RCTs that assessed the efficacy of remdesivir versus placebo or standard of care. The primary endpoint will be time to clinical recovery.
... Review and Meta-Analysis Protocols (PRISMA-P) 2015 guidelines for the design and reporting of the results. We will include RCTs that assessed the efficacy of remdesivir versus placebo or standard of care. The primary endpoint will be time to clinical recovery. The secondary endpoints will be proportion of participants relieved from clinical symptoms defined at the ...
Ref: cord_uid kcrmi3x8 Efficacy of remdesivir in patients with COVID-... kcrmi3x8 Efficacy of remdesivir in patients with COVID-... Name: title, dtype: object [Eur J Pharmacol, cord_uid kcrmi3x8 2020 kcrmi3x8 2020 Name: publish_time, dtype: object]clinical trials suggest that remdesivir speeds recovery from COVID-19.
... research, the targeted antivirals remdesivir and favipiravir appear to benefit patients by decreasing viral replication; clinical trials suggest that remdesivir speeds recovery from COVID-19. Tocilizumab and baricitinib appear to improve mortality by preventing a severe cytokine storm. Convalescent plasma ...
Ref: Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review [Viruses, 2020]remdesivir was approved by the Food and Drug Administration to treat COVID-19 through Emergency Use Authorization.
... new treatments, cures, and supporting apparatuses. Recently, because of its positive results in clinical trials, remdesivir was approved by the Food and Drug Administration to treat COVID-19 through Emergency Use Authorization. Here, we used molecular dynamics simulations and free energy perturbation methods to study the inhibition ...
Ref: cord_uid oheezbz8 Structural Basis of the Potential Binding Mech... oheezbz8 Structural Basis of the Potential Binding Mech... oheezbz8 Structural Basis of the Potential Binding Mech... Name: title, dtype: object [Viruses, cord_uid oheezbz8 2020 oheezbz8 2020 oheezbz8 2020 Name: publish_time, dtype: object]Remdesivir appears to be promising in the treatment of novel coronavirus disease 2019 .
... Remdesivir appears to be promising in the treatment of novel coronavirus disease 2019 . However, the evaluation of the effectiveness of remdesivir should be done in parallel with the analysis of its adverse events since only little is known about its safety. In fact, ...
Ref: Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 [Eur J Clin Pharmacol, 2020-10-04]Newer randomized controlled studies that have recently become available, showed a mixed result.
... for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of ...
Ref: Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies [Diabetes Metab Syndr, 2020]Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial.
... and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of ...
Ref: cord_uid u3lfjgqk Case report study of the first five COVID-19 p... u3lfjgqk Case report study of the first five COVID-19 p... Name: title, dtype: object [Diabetes Metab Syndr, cord_uid u3lfjgqk 2020 u3lfjgqk 2020 Name: publish_time, dtype: object]48 clinical trials were identified,
... the treatment of COVID-19 at the clinicaltrials gov database on April 2, 2020 In total, 48 clinical trials were identified, and of these, 41 trials adopted drug intervention and the other 7 trials utilized biological ...
Ref: Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan [Global Health & Medicine, 2020]time to a positive outcome, such as recovery or improvement, has repeatedly been used as either the primary or key secondary end point.
... harm, are needed. In recently published and ongoing randomized comparative trials evaluating treatments for COVID-19, time to a positive outcome, such as recovery or improvement, has repeatedly been used as either the primary or key secondary end point. Because patients may die before recovery or improvement, data analysis of this end point faces ...
Ref: How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19 [Ann Intern Med, 2020-07-07]In Phase 1 clinical trials in healthy volunteers, grade 1 and 2 transaminase elevations were observed which resolved after discontinuation.
... inhibitor with activity against the novel SARS-CoV-2 virus used in the treatment of COVID-19 pneumonia. In Phase 1 clinical trials in healthy volunteers, grade 1 and 2 transaminase elevations were observed which resolved after discontinuation. 7 In a randomized, double-blind, placebo-controlled trial of 1063 hospitalized patients with COVID-19, there was ...
Ref: Acetylcysteine for the Treatment of Suspected Remdesivir‐Associated Acute Liver Failure in COVID‐19: A Case Series [Pharmacotherapy, 2020-10-02]Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak.
... (GS-5734), a broad-spectrum antiviral that was initially developed for the treatment of Ebola virus (EBOV). Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2, uncontrolled clinical ...
Ref: The journey of remdesivir: from Ebola to COVID-19 [Drugs Context, 2020-05-22]The results of an open RCT evaluating lopinavir/ritonavir for COVID-19 were published on 18 March 2020.
... spatial structure of the lopinavir/ ritonavir binding site was conserved between SARS-CoV and SARS-CoV-2. 15 The results of an open RCT evaluating lopinavir/ritonavir for COVID-19 were published on 18 March 2020. 16 In this trial, adults with confirmed COVID-19 and hypoxaemia (SpO 2 <94 %) were ...
Ref: Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults [BMJ Open, 2020-09-21]Few of them are in the advanced stage of clinical trials including Remdesivir.
... number of nucleic acid based anti-viral drugs are being repurposed for treating COVID-19 targeting RdRp. Few of them are in the advanced stage of clinical trials including Remdesivir. While performing close investigation of the large set of nucleic acid based drugs, we were ...
Ref: Design and in-silico screening of Peptide Nucleic Acid (PNA) inspired novel pronucleotide scaffolds targeting COVID-19. [Current computer-aided drug design, 2020-09-23]Data from several ongoing randomized controlled trials will provide further evidence regarding the safety and efficacy of these drugs for COVID-19.
... high-risk cases. The EMA recommends use of remdesivir for COVID-19 on a compassionate basis. Guidelines are issued for use of convalescent plasma in patients with serious or immediately life-threatening COVID-19. Data from several ongoing randomized controlled trials will provide further evidence regarding the safety and efficacy of these drugs for COVID-19. ...
Ref: Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update [Current computer-aided drug design, 2020-05-16]This article discusses its mode of action, indications, clinical trial efficacy and side-effects.
The antiviral remdesivir (Veklury) is the first drug to be licensed for the treatment of COVID-19. This article discusses its mode of action, indications, clinical trial efficacy and side-effects.
Ref: Remdesivir: an antiviral for the treatment of COVID-19 [Prescriber, 2020]In numerous clinical trials, efficaciousness of Remdesivir (GS-5734) against Ebola virus has been incontestable.
... Remdesivir has demonstrated potent antiviral activity against numerous human and animal disease β-coronaviruses, including SARS-CoV-2. In numerous clinical trials, efficaciousness of Remdesivir (GS-5734) against Ebola virus has been incontestable. Moreover, Remdesivir could also be an efficient medical aid in vitro and in animal models ...
Ref: Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2 [Eur J Pharmacol, 2020-10-13]This trial enrolled 1059 patients (538 assigned to remdesivir and 521 to placebo).
... of intravenous remdesivir in adults hospitalized with COVID-19 with evidence of lower respiratory tract involvement. This trial enrolled 1059 patients (538 assigned to remdesivir and 521 to placebo). The primary end point of the original analysis was the recovery time, defined by either ...
Ref: Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir [Eur J Pharmacol, 2020-06-19]As of July 30, 2020, a total of 36,640 relevant documents were published.
... was based on keywords "COVID-19" SARS-COV-2, chloroquine, hydroxychloroquine, convalescent plasma, remdesivir and treatment modalities. Results: As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 ...
Ref: Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis [Eur J Pharmacol, 2020]Good outcomes have been reported in 8 cases report (2;3).
... respiratory syndrome coronavirus (MERS-CoV), 7 remdesivir appears to be effective in vitro in SARS-Cov2 (1). Good outcomes have been reported in 8 cases report (2;3). Many studies are ongoing or already published to demonstrate the efficacy of 9 remdesivir on ...
Ref: Remdesivir investigational trials in COVID-19: a critical reappraisal [New Microbes New Infect, 2020-06-07]Some of the current studies have demonstrated adverse drug reactions to chloroquine and hydroxychloroquine + azithromycin.
... promising early reports of in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2. Some of the current studies have demonstrated adverse drug reactions to chloroquine and hydroxychloroquine + azithromycin. Widespread systemic inflammation and procoagulant/hypercoagulable state, including thrombotic microangiopathy, endothelial dysfunction, bleeding disorder, and thrombosis ...
Ref: Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned [Vascular, 2020]Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19),
... Importance: Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown. Objective: To determine the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical ...
Ref: cord_uid tq2u4ssx Effect of Remdesivir vs Standard Care on Clini... tq2u4ssx Effect of Remdesivir vs Standard Care on Clini... Name: title, dtype: object [Vascular, cord_uid tq2u4ssx 2020 tq2u4ssx 2020 Name: publish_time, dtype: object]For the moderate cases [11] , the primary endpoint was time to discharge in 5 to 10 days.
... On March 3, 2020, Gilead Science launched two clinical trials of remdesivir [11, 12] . For the moderate cases [11] , the primary endpoint was time to discharge in 5 to 10 days. For the severe cases [12] , the primary endpoint was proportion of participants with normalization ...
Ref: Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis [Drug Inf J, 2020-05-16]Remdesivir is currently the most promising molecule in the treatment of COVID-19,
... PUBMED On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it ...
Ref: Use of remdesivir for patients with Covid-19: a review article [Revista da Associacao Medica Brasileira (1992), 2020]an assessment of clinical trials for COVID-19 emerging therapies on ClinicalTrials.gov produced 1,154 search results.
... As of June 29, 2020, an assessment of clinical trials for COVID-19 emerging therapies on ClinicalTrials.gov produced 1,154 search results. The number and type of trials for the therapies included in this review are summarized in Table 2 . Emerging trials of note include the ...
Ref: A narrative review of emerging therapeutics for COVID-19 [Mayo Clin Proc Innov Qual Outcomes, 2020-07-20]However, double-blind, randomized controlled trials are required to investigate their safety and efficacy.
... to be the most promising drug for the treatment of pneumonia caused by COVID-19 pneumonia. Many other agents or strategies are being tested for the treatment of patients with COVID-19. However, double-blind, randomized controlled trials are required to investigate their safety and efficacy. ...
Ref: Emerging Therapeutic Strategies for COVID-19 patients [Discoveries, 2020-03-12]A single, small, randomized and placebo-controlled trial demonstrated evidence for a survival benefit of azathioprine (AZT).
... of any known effective treatments, there was substantial resistance to the conduct of placebo-controlled trial. A single, small, randomized and placebo-controlled trial demonstrated evidence for a survival benefit of azathioprine (AZT). Although this amount of information was less than would typically be needed to support approval ...
Ref: Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven [Contemp Clin Trials Commun, 2020-10-07]200 mg on day 1 followed by 100 mg from day 2 to 10 depending on the clinical assessment [36] .
... healthy volunteers in EBOV, Gilead recommended the dosage and duration of treatment for remdesivir as 200 mg on day 1 followed by 100 mg from day 2 to 10 depending on the clinical assessment [36] . The access of remdesivir in COVID-19 pandemic was made possible through several regulatory approaches within ...
Ref: The use of remdesivir outside of clinical trials during the COVID-19 pandemic [J Pharm Policy Pract, 2020-09-21]Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance.
... treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately ...
Ref: Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. [Cancer discovery, 2020-07-22]In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.
... clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection. 2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir ...
Ref: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. [Nature, 2020-06-09]Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect.
... multi-country trial has shown a significant faster time to recovery but without any difference in mortality. CONCLUSIONS: Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials. ...
Ref: Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies [Diabetes Metab Syndr, 2020-05-12]no efficacy results against COVID-19 with either of these combinations have been reported from well-controlled trials during the time period of our review.
... late stage infections. The 4-aminoquinoline treatments might benefit from supplementation with zinc and/or azithromycin, however no efficacy results against COVID-19 with either of these combinations have been reported from well-controlled trials during the time period of our review. Immediate passive immunization in our series, although tested to only a limited extent, has generated ...
Ref: Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis [J King Saud Univ Sci, 2020-09-06]Here we validated our hypothesis by comparing the pharmacokinetics profiles of these drugs and their capabilities of reducing viral load in clinical trials.
... hydroxychloroquine, azithromycin, favipiravir, ribavirin, darunavir, remdesivir, and umifenovir have been tested in COVID-19 clinical trials. Here we validated our hypothesis by comparing the pharmacokinetics profiles of these drugs and their capabilities of reducing viral load in clinical trials. According to bulk RNA and single cell RNA sequencing analysis, we found that high expression ...
Ref: Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment [Eur J Pharmacol, 2020]Our findings synthesize results of primary and secondary outcomes of ongoing or completed clinical trials (19) (20) (21) .
... trends of in-hospital mortality, oxygen support status and adverse events within two weeks of treatment. Our findings synthesize results of primary and secondary outcomes of ongoing or completed clinical trials (19) (20) (21) . However, our findings ought to be interpreted cautiously. We found over 35 trials registered on ...
Ref: Randomized placebo-controlled trials of remdesivir in severe COVID-19 patients: A Systematic Review and Meta-analysis [Eur J Pharmacol, 2020-08-24]all of its side effects have not yet been defined.
... side effects. [18] Remdesivir (GS-5734, Gilead Sciences Inc.) is currently under several clinical trials and all of its side effects have not yet been defined. In our patient, within 2 days of starting remdesivir our patient had worsening renal function ...
Ref: Novel coronavirus 2019 (COVID-19): A case report and review of treatments [Medicine (Baltimore), 2020-05-08]Most COVID-19 trials were designed to follow patients for only 3-4 weeks.
... Most COVID-19 trials were designed to follow patients for only 3-4 weeks. However, patients with severe illness, especially those experiencing prolonged ventilation or developing acute respiratory distress syndrome with a fibrotic component, may have unfavorable longterm outcomes. In addition, patients may require ...
Ref: Evaluating the Efficacy of Therapies in COVID-19 Patients [Clin Infect Dis, 2020-08-21]not all of these RCTs generated consistent evidence [3] [4] [5] .
... authorization for the disease by the United States Food and Drug Administration [2] . However, not all of these RCTs generated consistent evidence [3] [4] [5] . As such, the present study aimed to synthesize available RCT evidence using network meta-analyses (NMAs). ...
Ref: Effectiveness of remdesivir for the treatment of hospitalized Covid‐19 persons: a network meta‐analysis [J Med Virol, 2020-08-19]However, the substance failed in a clinical trial on ebolavirus disease (EVD),
... showed therapeutic and prophylactic effects in animal models of EBOV, MERS-CoV, SARS-CoV, and SARS-CoV-2 infection. However, the substance failed in a clinical trial on ebolavirus disease (EVD), where it was inferior to investigational monoclonal antibodies in an interim analysis. As there was ...
Ref: Remdesivir against COVID-19 and Other Viral Diseases [Clin. microbiol. rev, 2020]Of the 53 patients with severe COVID-19, 36 patients (68%) showed clinical improvement, 25 patients (47%) were discharged.
... April 2020, Gilead Sciences Inc., published the first clinical result of compassionate-use remdesivir [12] . Of the 53 patients with severe COVID-19, 36 patients (68%) showed clinical improvement, 25 patients (47%) were discharged. whereas eight patients (15%) showed worsening and seven patients (13%) died. A total of 32 ...
Ref: Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2 [Future medicinal chemistry, 2020-07-08]From 708 identified studies or clinical trials, 16 studies and 16 case reports met our eligibility criteria Of these,
... systematic review adheres to the PRISMA guidelines The protocol is available at PROSPERO (CRD42020180915) RESULTS: From 708 identified studies or clinical trials, 16 studies and 16 case reports met our eligibility criteria Of these, 6 were randomized controlled trials (763 patients), 7 cohort studies (321 patients) and 3 case ...
Ref: Repurposing of drugs for Covid-19: a systematic review and meta-analysis [Panminerva Med, 2020]The clinical trials on JAKs are given in Table 5 .
... process. Baricitinib can disrupt AAK1 causing the interruption of viral entry into the cell and intracellular assembly of virus particles, which makes it a potential drug for COVID-19 [22] . The clinical trials on JAKs are given in Table 5 . ...
Ref: Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts [Cureus, 2020-06-26]Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses.
... received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. The remdesivir core contains GS-441524, which interferes with RNA-dependent RNA polymerases alone. In non-human primates, ...
Ref: Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease [J Antimicrob Chemother, 2020]Grade 3 and 4 ALT and/or AST elevations occurred in 7% patients.
... the a remdesivir clinical trial comparing 5 and 10day treatment courses in patients with COVID-19, Grade 3 and 4 ALT and/or AST elevations occurred in 7% patients. Elevations in bilirubin were uncommon (1.3%). 23 At this time, it is unclear if the ...
Ref: Remdesivir: Review of pharmacology, pre‐clinical data and emerging clinical experience for COVID‐19 [Pharmacotherapy, 2020-05-23]our data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.
... early during infection had a clinical benefit in rhesus macaques infected with SARS-CoV-2. Although the rhesus macaque model does not represent the severe disease observed in some patients with COVID-19, our data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia. ...
Ref: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 [Nature, 2020]Ongoing randomised controlled trials will clarify its real efficacy and safety, who to treat, and when.
... of the cases, respectively). Our data suggest that remdesivir can benefit patients with SARS-CoV-2 pneumonia hospitalised outside ICU where clinical outcome was better and adverse events are less frequently observed. Ongoing randomised controlled trials will clarify its real efficacy and safety, who to treat, and when. ...
Ref: cord_uid 32azjzu5 Compassionate remdesivir treatment of severe C... 32azjzu5 Compassionate remdesivir treatment of severe C... Name: title, dtype: object [Nature, cord_uid 32azjzu5 2020 32azjzu5 2020 Name: publish_time, dtype: object]COVID-19 trials have rated clinical status on an ordinal scale of severity rating, with 6, 7, or 8 points.
... COVID-19 trials have rated clinical status on an ordinal scale of severity rating, with 6, 7, or 8 points. The rating system covers a multitude of important clinical outcomes, favorable or unfavorable. We propose two approaches for using the daily severity ratings over the follow-up period of interest to ...
Ref: Evaluating the Efficacy of Therapies in COVID-19 Patients [Clin Infect Dis, 2020-08-21]The few trials that allow their inclusion focus on postexposure prophylaxis or outpatient treatment of milder disease,
... the continued near-universal regressive practice of exclusion of pregnant and breastfeeding women from these trials. The few trials that allow their inclusion focus on postexposure prophylaxis or outpatient treatment of milder disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use of remdesivir, ...
Ref: Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19 Therapeutic Trials [Clin Infect Dis, 2020]To date, more than 50 clinical trials have registered in China for the evaluation of TCM in COVID-19.
... China has reported the beneficial effect of TCM in around more than 60,000 COVID-19 patients. To date, more than 50 clinical trials have registered in China for the evaluation of TCM in COVID-19. Luo, et al. has shortlisted ten most commonly used TCM in China, and they are ...
Ref: Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update [Curr Pharmacol Rep, 2020-07-18]Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment.
... diverse RNA virus families, including positive-sense Coronaviridae and Flaviviridae and negative-sense Filoviridae, Paramyxoviridae, and Pneumoviridae. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, ...
Ref: Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition [Front. Microbiol., 2020]Results of these trials are not available yet.
... drug is effective. Remdesivir is now being evaluated in COVID-19 patients in five clinical studies worldwide: two studies in China, and studies in the United States, Singapore and South Korea. Results of these trials are not available yet. ...
Ref: Medical treatment options for COVID-19 [Eur Heart J Acute Cardiovasc Care, 2020-05-04]The pharmacokinetics of remdesivir have not been evaluated in patients >65 years of age.
... The pharmacokinetics of remdesivir have not been evaluated in patients >65 years of age. In general, appropriate caution should be exercised in the administration of remdesivir and monitoring of elderly patients. 63 ...
Ref: Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients [Drug Des Devel Ther, 2020-07-28]of 1063 patients, 541 were assigned at random to remdesivir and 522 to placebo.
... treatment. Not surprisingly, remdesivir attracted worldwide attention. In a trial published online ahead of print, of 1063 patients, 541 were assigned at random to remdesivir and 522 to placebo. The primary prespecified endpoint was mean recovery time and patients assigned to remdesivir had a ...
Ref: Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven [Contemp Clin Trials Commun, 2020]More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19.
... in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria ...
Ref: Clinical trials on drug repositioning for COVID-19 treatment/ Ensayos clínicos de reposicionamiento de medicamentos para el tratamiento de la COVID-19/ Ensaios clínicos de reposicionamento de medicamentos para o tratamento do COVID-19 [Rev. panam. salud pública, 2020]Results Two RCTs studies were identified (n=1,299).
... method was applied to rate the certainty and quality of the evidence reported per study. Results Two RCTs studies were identified (n=1,299). A fixed-effects meta-analysis revealed reductions in mortality (RR=0.69, 0.49 to 0.99), time to clinical improvement ...
Ref: Remdesivir use in patients with coronavirus COVID-19 disease: a systematic review and meta-analysis [Rev. panam. salud pública, 2020-05-26]clinical improvement was observed in 36 of 53 patients (68%) [25] .
... a cohort of patients hospitalized for severe Covid-19 who were treated with compassionate use remdesivir, clinical improvement was observed in 36 of 53 patients (68%) [25] . As there was no placebo or active comparator in this study, it is hard to ...
Ref: Antiviral treatment of COVID-19 [Turk J Med Sci, 2020-04-21]two small clinical trials, one of which was not randomized and did not study clinical outcomes.
... two small clinical trials, one of which was not randomized and did not study clinical outcomes. 2 More clinical trial data are needed to determine whether hydroxychloroquine has a role in treatment or postexposure prophylaxis in COVID-19. ...
Ref: Off‐Label Therapies for COVID‐19—Are We All In This Together? [Clin Pharmacol Ther, 2020-05-05]remdesivir at 6.25 µM in combination with emetine at 0.195 µM may achieve 64.9% inhibition in viral yield.
... trials showed no inhibition at 100 µM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 µM in combination with emetine at 0.195 µM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma ...
Ref: Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro [Antiviral Res, 2020]has thus far yielded promising results.
... Phase III evaluation of remdesivir in the treatment of COVID-19 commenced in early 2020 and has thus far yielded promising results. In late May 2020, Taiwan conditionally approved the use of remdesivir in patients with severe ...
Ref: Remdesivir: First Approval [Drugs, 2020]The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial.
... signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions. The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. It may also be considered for a wider range of coronaviruses, including the currently emerging ...
Ref: cord_uid x1fzgiy6 Prophylactic and therapeutic remdesivir (GS-57... x1fzgiy6 Prophylactic and therapeutic remdesivir (GS-57... Name: title, dtype: object [Drugs, cord_uid x1fzgiy6 2020 x1fzgiy6 2020 Name: publish_time, dtype: object]RESULTS According to the articles reviewed, a total of 279 drugs interact with Remdesivir.
... key terms remdesivir, drug interactions and dentistry for articles published up to 31st July 2020. RESULTS According to the articles reviewed, a total of 279 drugs interact with Remdesivir. Two major interactions have been reported, 277 moderate drug interactions, and one with alcohol/food. The ...
Ref: Remdesivir-COVID-19: drug interactions in dentistry. [European review for medical and pharmacological sciences, 2020-09-01]Currently, it was demonstrated that this combination has no benefits in adult patients with severe Covid-19 [45] .
... of lopinavir/ritonavir with or without ribavirin is evaluated in SARS-CoV-2 patients under randomized control trials. Currently, it was demonstrated that this combination has no benefits in adult patients with severe Covid-19 [45] . Although protease inhibitors are a common class of medication used in the treatment of HIV-1 ...
Ref: Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2 [Biomed Pharmacother, 2020-08-24]remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use.
... known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir ...
Ref: Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review [J. microbiol. immunol. infect, 2020]There have been more than 300 clinical trials going on,
... is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those ...
Ref: Antiviral treatment of COVID-19 [Turk J Med Sci, 2020]Currently, several clinical trials using remdesivir as a treatment for infected COVID-19 patients are undergoing around the world.
... the first severely infected COVID-19 patient in the United States in 24 hours (19) . Currently, several clinical trials using remdesivir as a treatment for infected COVID-19 patients are undergoing around the world. The first phase III clinical trial which is conducted in China is expected to be ...
Ref: Remdesivir inhibits renal fibrosis in obstructed kidneys [bioRxiv, 2020-04-03]one with arbidol in comparison with the basic treatment (25) ,
... As shown in Table 1 , four clinical trials will be conducted for COVID-19 treatment: one with arbidol in comparison with the basic treatment (25) , and the other three studies comparing effects with oseltamivir (26, 27) , lopinavirritonavir (27) , ...
Ref: Clinical trials on drug repositioning for COVID-19 treatment [Rev Panam Salud Publica, 2020-03-20]remdesivir yielded positive results in preclinical models of Ebola virus infection but was inferior to two monoclonal antibody therapies in treated patients [15] .
... severe COVID-19, both because of its uncertain antiviral efficacy and the unclear importance of ongoing viral replication versus an inflammatory process in disease pathogenesis in severely ill patients. Of note, remdesivir yielded positive results in preclinical models of Ebola virus infection but was inferior to two monoclonal antibody therapies in treated patients [15] . ...
Ref: Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial [Trials, 2020-05-24]Remdesivir for non-ventilated patients and dexamethasone for ventilated patients was estimated to result in 1,111 deaths averted
... in 2020 USD, deaths averted, and the incremental cost effectiveness ratios of each scenario Results Remdesivir for non-ventilated patients and dexamethasone for ventilated patients was estimated to result in 1,111 deaths averted (assuming a 0-30% efficacy of remdesivir) compared to standard care, and save $11 5 million ...
Ref: Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa [medRxiv, 2020]Gilead Sciences’ experimental antiviral remdesivir helped people with COVID-19 recover faster,
... Gilead Sciences’ experimental antiviral remdesivir helped people with COVID-19 recover faster, according to limited data released on April 29 from a trial led by the US National Institute of Allergy and Infectious Diseases The Food and Drug Administration is expected in ...
Ref: Remdesivir data offer hope, with caveats [C&EN Global Enterprise, 2020]Gilead Science's remdesivir has been introduced to China through special approval procedures, and was directly conducting the Phase III clinical trial.
... New drugs against the in COVID-19 pandemic are urgently needed. Gilead Science"s remdesivir has been introduced to China through special approval procedures, and was directly conducting the Phase III clinical trial. As expected, the marketing authorization process was completed soon. The drug brought hope to patients as well as business opportunities ...
Ref: Were it business opportunities or hidden risks: Observations on clinical trials and marketing authorizations of Gilead Science's remdesivir in China [Pharmazie, 2020]